Publikationen, an denen er mitarbeitet Mariano Provencio Pulla (15)

2024

  1. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2022

  1. Future care for long-term cancer survivors: towards a new model

    Clinical and Translational Oncology, Vol. 24, Núm. 2, pp. 350-362

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  3. Lung cancer in Spanish women: The WORLD07 project

    European Journal of Cancer Care, Vol. 28, Núm. 1

2018

  1. Abemaciclib in combination with single-agent options in patients with stage IV non–small cell lung cancer: A phase Ib study

    Clinical Cancer Research, Vol. 24, Núm. 22, pp. 5543-5551

2017

  1. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

    Clinical Lung Cancer, Vol. 18, Núm. 2, pp. 178-188.e4

  2. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

  3. Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

    Cancer Investigation, Vol. 35, Núm. 5, pp. 358-365

2016

  1. Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07

    Anticancer Research, Vol. 36, Núm. 12, pp. 6647-6653

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

  2. Lung adenocarcinoma

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 136-165

2010

  1. New molecular targeted therapies integrated with radiation therapy in lung cancer

    Clinical Lung Cancer, Vol. 11, Núm. 2, pp. 91-97

2009

  1. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

    Clinical and Translational Oncology

2007

  1. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: The Spanish Lung Cancer Group trial 9901

    Journal of Clinical Oncology, Vol. 25, Núm. 30, pp. 4736-4742